Biological
Recombinant Fowlpox-TRICOM Vaccine clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2001
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2001 (2)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2007 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 5
National Cancer Institute (NCI) (4) · National Institute on Deafness and Other Communication Disorders (NIDCD) (1)
Often tested with
Tested in the same studies.
Sargramostim (1) · rV-Tricom (1) · Recombinant Fowlpox GM-CSF Vaccine Adjuvant (1) · rF-B7.1 vaccine (1)
Studies
Open first, then newest update. How each study uses Recombinant Fowlpox-TRICOM Vaccine is read from its arms, and is right about nine times in ten.
Testing it · 5
- 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT00450619Written as Recombinant fowlpox-TRICOM vaccine
- Vaccine Therapy in Treating Patients With Stage IV Head and Neck CancerCompletedPhase 1National Institute on Deafness and Other Communication Disorders (NIDCD)NCT00021424Written as recombinant fowlpox-TRICOM vaccine
- Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing CystectomyTerminatedPhase 1National Cancer Institute (NCI)NCT00072137Written as Recombinant Fowlpox-TRICOM Vaccine
- Vaccine Therapy in Treating Patients With Metastatic MelanomaTerminatedPhase 2National Cancer Institute (NCI)NCT00087373Written as recombinant fowlpox-TRICOM vaccine
- Vaccine Therapy in Treating Patients With Metastatic Solid TumorsTerminatedPhase 1National Cancer Institute (NCI)NCT00030693Written as recombinant fowlpox-TRICOM vaccine